In this article, we will discuss Dinutuximab (Dosage Overview). So, let’s get started.
Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of
pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
• Verify that patients have adequate hematologic, respiratory, hepatic, and renal function prior to initiating each course of Dinutuximab.
• Administer required premedication and hydration prior to initiation of each Unituxin infusion.
The recommended dose of Unituxin is 17.5 mg/m2/day administered as an intravenous
infusion over 10 to 20 hours for 4 consecutive days for a maximum of 5 cycles.
Initiate at an infusion rate of 0.875 mg/m2/hour for 30 minutes. The infusion rate can be gradually increased as tolerated to a maximum rate of 1.75 mg/m2/hour.